—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation—

——支持BioCryst向以外部创新为核心的更严谨的研发模式转型——

RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development.

北卡罗来纳州研究三角园，2026年10月5日（环球社电）——BioCryst Pharmaceuticals, Inc.（纳斯达克股票代码：BCRX）今日宣布成立科学顾问委员会（SAB），该委员会由七位杰出的科学界和业界领袖组成，他们在罕见病研究和药物开发领域拥有深厚的专业知识。

The SAB will provide independent scientific and strategic guidance as the Company advances its research and development strategy and builds a high value novel drug pipeline..

随着公司推进其研发战略并构建高价值的创新药物管线，科学顾问委员会（SAB）将提供独立的科学与战略指导。

“The formation of BioCryst’s Scientific Advisory Board marks an important step in the evolution of our new R&D model,” said Dr. Sandeep Menon, BioCryst’s Chief Research and Development Officer. “External innovation is increasingly central to how we build our pipeline, and guidance from leading scientists and physicians will sharpen our thinking and strengthen the diligence behind each program we evaluate and advance.

“BioCryst科学顾问委员会的成立，标志着我们新研发模式演进中的重要一步。”BioCryst首席研发官Sandeep Menon博士表示，“外部创新在我们构建产品管线的过程中正日益占据核心地位，而来自顶尖科学家和临床医生的指导将帮助我们厘清思路，并加强对每个我们评估和推进项目的尽职调查力度。”

The Scientific Advisory Board will work closely with me and our Chief Scientific Officer, Dr. David Jenkins, as we shape and execute BioCryst’s R&D strategy.”.

“科学顾问委员会将与我及我们的首席科学官戴维·詹金斯博士紧密合作，共同制定并执行BioCryst的研发战略。”

“Building on our success in developing and commercializing medicines for hereditary angioedema, we are bringing the same rigor to the next generation of BioCryst medicines,” said Charlie Gayer, Chief Executive Officer. “With the expertise of these highly experienced scientific advisors, BioCryst will be better positioned to evaluate emerging opportunities and translate their potential into meaningful benefits for patients.”.

“基于我们在遗传性血管性水肿药物的开发和商业化方面取得的成功，我们将以同样的严谨态度推进BioCryst下一代药物的研发，”首席执行官Charlie Gayer表示。“凭借这些经验丰富的科学顾问的专业知识，BioCryst将能更好地评估新兴机遇，并将其潜力转化为为患者带来切实获益的成果。”

The SAB will provide strategic guidance across BioCryst’s research and development activities, including pipeline expansion, external innovation opportunities, translational science and clinical development. The board will also offer insights on regulatory strategy and help strengthen connections with leading scientific, medical and patient communities worldwide..

科学咨询委员会（SAB）将为BioCryst的研发活动提供战略指导，包括管线拓展、外部创新机会、转化科学以及临床开发。该委员会还将就监管策略提供见解，并帮助加强公司与全球领先的科学界、医学界及患者群体之间的联系。

'Few companies have demonstrated BioCryst’s ability to translate rigorous science into rare disease medicines that reach patients, and that track record is what makes the Company’s evolution so compelling,' said Dr. Anthony Manning, Chair of the Scientific Advisory Board. 'The formation of this Board is an important step for BioCryst, and it is a privilege to chair a group with this depth of experience across rare disease drug discovery, translational science and clinical development.

“很少有公司能像BioCryst那样，展现出将严谨的科学转化为惠及患者的罕见病药物的能力，而这一记录正是使该公司的发展如此引人注目的原因。”科学顾问委员会主席Anthony Manning博士表示。“该委员会的成立是BioCryst的重要一步，能够领导一个在罕见病药物发现、转化科学和临床开发方面拥有如此深厚经验的团队，我深感荣幸。”

I am confident the Company’s decisions about which science to pursue and how to advance it will benefit from the collective judgment of its members.'.

我相信，公司在决定 pursue 哪些科学领域以及如何推进这些领域时，将从其成员的集体判断中受益。

Scientific Advisory Board Members:

科学顾问委员会成员：

Anthony (Tony) Manning, PhD, Chair,

安东尼（托尼）曼宁博士，主席，

is Principal at Manning Bio Worldwide, LLC, advising biotechnology companies and academic institutions following a 30-year career in pharmaceutical drug discovery and development. As Chief Scientific Officer at Momenta Pharmaceuticals (now part of Johnson & Johnson), he built a pipeline of first-in-class therapeutics for rare autoantibody-driven diseases, including nipocalimab (IMAAVY), now FDA-approved for generalized myasthenia gravis and warm autoimmune hemolytic anemia, with additional indications in development.

现任 Manning Bio Worldwide, LLC 负责人，在拥有三十年药物发现与开发职业经历后，为生物技术公司和学术机构提供咨询。此前，他在 Momenta Pharmaceuticals（现为强生公司旗下子公司）担任首席科学官期间，构建了针对罕见自身抗体驱动疾病的首创疗法产品管线，其中包括已获美国食品药品监督管理局（FDA）批准用于治疗全身型重症肌无力和温性自身免疫性溶血性贫血的 nipocalimab（IMAAVY），另有多个适应症正在开发中。

Earlier, he led drug discovery efforts at Roche Pharmaceuticals and Biogen Idec, contributing to the approvals of Actemra and Rituxan, and to the development of litifilimab, now in Phase 3 for lupus..

此前，他在罗氏制药和Biogen Idec领导药物研发工作，为Actemra和Rituxan的获批以及litifilimab的研发做出了贡献，后者目前正处于治疗狼疮的三期临床试验阶段。

Dr. Christine Bulawa, PhD,

克里斯汀·布拉瓦博士，哲学博士，

received a PhD from the University of Wisconsin-Madison and completed postdoctoral studies at Massachusetts Institute of Technology (MIT). As part of her 20+ years in rare disease drug discovery, she was the first employee of FoldRx Pharmaceuticals and instrumental in the preclinical development of tafamidis, the first pharmacological treatment for transthyretin amyloidosis.

在威斯康星大学麦迪逊分校获得博士学位，并在麻省理工学院（MIT）完成博士后研究。在罕见病药物发现领域拥有二十余年经验，她是FoldRx Pharmaceuticals的首位员工，并在转甲状腺素蛋白淀粉样变性症的首个药物治疗药物——塔法米迪斯的临床前开发中发挥了关键作用。

As a senior leader in Pfizer’s Rare Disease Research Unit, Dr. Bulawa built a pipeline of innovative programs based on rigorously validated targets, spanning portfolio entry to clinical development, with a focus on small molecule and genetic therapies to treat degenerative neurological, neuromuscular and protein aggregation diseases. .

作为辉瑞罕见病研究部门的高级领导，Bulawa博士构建了一条基于严格验证靶点的创新项目管线，涵盖从项目立项到临床开发的全过程，重点聚焦于治疗退行性神经疾病、神经肌肉疾病和蛋白质聚集性疾病的小分子药物和基因疗法。

Dr. Eric A. Hughes, MD, PhD,

埃里克·A·休斯博士，医学博士，哲学博士，

serves as Executive Vice President, Global Research & Development and Chief Medical Officer at Teva Pharmaceuticals. A physician-scientist who earned his MD and PhD from Yale University, Dr. Hughes brings nearly 20 years of biopharmaceutical industry experience and is helping advance Teva’s transformation into a leading innovative biopharmaceutical company, enabled by a world-class generics business.  Prior to Teva, he served in leadership roles at Vertex, Novartis and Bristol Myers Squibb..

在梯瓦制药公司（Teva Pharmaceuticals）担任执行副总裁，主管全球研发并兼任首席医疗官。休斯博士是一位医师科学家，拥有耶鲁大学医学博士和哲学博士学位，他在生物制药行业拥有近20年的经验，正助力梯瓦转型为一家由世界一流仿制药业务支撑的领先创新型生物制药公司。在加入梯瓦之前，他曾在福泰制药（Vertex）、诺华（Novartis）和百时美施贵宝（Bristol Myers Squibb）担任领导职务。

Dr. Stephanie Noviello, MD, MPH,

斯蒂芬妮·诺维洛博士，医学博士，公共卫生硕士

is Chief Medical Officer at ILiAD Biotechnologies, Inc. She is a clinical development leader with extensive experience across infectious diseases, virology, immunology, rare diseases and skeletal diseases at Novartis, Motif BioSciences, Bristol-Myers Squibb and Schering-Plough Research Institute.

担任ILiAD Biotechnologies, Inc.的首席医学官。她是一位临床开发领导者，在诺华、Motif BioSciences、百时美施贵宝和先灵葆雅研究所拥有传染病、病毒学、免疫学、罕见病和骨骼疾病领域的丰富经验。

Dr. Shashi Ramaiah, DVM, PhD, DACVP, DABT,

沙希·拉马亚博士，兽医博士，哲学博士，美国兽医病理学家学会认证专家，美国毒理学委员会认证专家

is a board-certified Veterinary Pathologist and Toxicologist who spent 18 years at Pfizer, most recently as Vice President and Global Head of Discovery, Investigative and Translational Sciences. He is Founder and CEO of SPECCRO, a drug development advisory firm that helps biotechnology companies and investors de-risk programs and portfolios, drawing on more than 40 senior industry experts and extensive engagement with national and international scientific consortia..

是一位拥有董事会认证的兽医病理学家和毒理学家，在辉瑞公司工作了18年，最近担任副总裁兼全球发现、调查和转化科学负责人。他是SPECCRO的创始人和首席执行官，这是一家药物开发咨询公司，帮助生物技术公司和投资者降低项目和投资组合的风险，依托40多位资深行业专家以及与国内外科学联盟的广泛合作。

Dr. Art Taveras, PhD,

阿特·塔韦拉斯博士，哲学博士，

is a seasoned biopharmaceutical executive with over 35 years of industry experience, specializing in leading R&D divisions across major public pharmaceutical corporations and biotech firms including Biogen Idec, Transform Therapeutics, X4 Pharmaceuticals, CoMET Therapeutics, ShangPharma ChemPartner, Alantos Pharmaceuticals and Schering-Plough.

是一位经验丰富的生物制药高管，拥有超过35年的行业经验，专长于领导多家大型上市制药公司和生物技术企业的研发部门，包括Biogen Idec、Transform Therapeutics、X4 Pharmaceuticals、CoMET Therapeutics、尚药化学伙伴（ShangPharma ChemPartner）、Alantos Pharmaceuticals以及先灵葆雅（Schering-Plough）。

His strategic expertise as President, CEO, CSO and R&D Leader has advanced robust pipelines and key global R&D partnerships, culminating in over 175 patent application filings, 150 publications, 60 clinical trials, 6 regulatory agency approvals and 5 therapeutic platform technologies across commercial and clinical-stage assets for diseases in neurology, oncology, immunology, metabolism and rare disease..

他在担任总裁、首席执行官、首席战略官及研发负责人期间，凭借卓越的战略专长，推动了强大的产品管线建设和关键全球研发合作伙伴关系的发展，最终成果包括提交175余项专利申请、发表150篇论文、开展60项临床试验、获得6项监管机构批准，并开发出5个治疗平台技术，涵盖针对神经学、肿瘤学、免疫学、代谢疾病和罕见病的商业化和临床阶段资产。

Dr. Ajay Yekkirala, PhD,

阿贾伊·耶基拉拉博士，哲学博士，

is an experienced serial entrepreneur who co-founded Superluminal Medicines at RA Capital and built a strong investor syndicate including NVIDIA, Eli Lilly, Insight Partners, Catalio, BVF and Perceptive Advisors. As Chief Scientific Officer, he directs the AI/ML platform build and all pipeline R&D. Prior to Superluminal, Dr.

是一位经验丰富的连续创业者，他在 RA Capital 共同创立了 Superluminal Medicines，并组建了一个强大的投资者联盟，包括英伟达（NVIDIA）、礼来公司（Eli Lilly）、Insight Partners、Catalio、BVF 和 Perceptive Advisors。作为首席科学官，他负责指导人工智能/机器学习平台的建设以及所有研发管线的研究工作。在加入 Superluminal 之前，博士

Yekkirala founded Blue Therapeutics to develop non-addictive painkillers. He received his PhD from the University of Minnesota and completed postdoctoral training at Harvard Medical School. He has authored several papers published in high-impact, peer-reviewed journals and advised various committees at the NIH, including EPPIC-NET at NINDS and Medication Development Research Committee at NIDA..

耶基拉拉创立了Blue Therapeutics，致力于开发非成瘾性止痛药。他于明尼苏达大学获得博士学位，并在哈佛医学院完成博士后培训。他在高影响力的同行评审期刊上发表了多篇论文，并担任美国国立卫生研究院（NIH）多个委员会的顾问，包括国家神经疾病与中风研究所（NINDS）的EPPIC-NET以及国家药物滥用研究所（NIDA）的药物开发研究委员会。

About BioCryst Pharmaceuticals

关于 BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases.

BioCryst 是一家全球性生物技术公司，专注于开发和商业化用于遗传性血管性水肿（HAE）及其他罕见病的药物，其动力源于改善这些患者生活的深切承诺。BioCryst 已实现 ORLADEYO®（berotralstat）的商业化，这是首款口服、每日一次的血浆激肽释放酶抑制剂，并正在推进一系列针对罕见病的潜在首创或同类最佳疗法的研发管线。

For more information, please visit .

欲了解更多信息，请访问。

www.biocryst.com

www.biocryst.com

or follow us on

或在以下平台关注我们

LinkedIn

领英

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements, including statements regarding future results, performance, or achievements, expectations regarding BioCryst’s strategic shift to prioritize external innovation, expectations regarding pipeline development, the anticipated role and potential benefits of BioCryst’s Scientific Advisory Board, and statements related to BioCryst’s future operations, prospects and pipeline programs.

本新闻稿包含前瞻性陈述，包括有关未来业绩、表现或成就的陈述；关于 BioCryst 战略转向以优先推动外部创新的预期；关于管线开发的预期；关于 BioCryst 科学顾问委员会的预期作用及潜在益处；以及有关 BioCryst 未来运营、前景和管线项目的陈述。

These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties.

这些陈述涉及已知和未知的风险、不确定性和其他因素，可能导致 BioCryst 的实际结果、业绩或成就与前瞻性陈述中明示或暗示的任何未来结果、业绩或成就存在重大差异。这些陈述反映了我们对未来事件的当前看法，基于某些假设，并受风险和不确定性的影响。

Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully progress its pipeline development plans; guidance and recommendations provided by the Scientific Advisory Board may not improve BioCryst’s evaluation or advancement of potential programs or result in the anticipated benefits; the commercial viability of BioCryst’s future rare disease therapies; ongoing and future development of product candidates may take longer than expected and may not have positive results; product candidates, if approved, may not achieve market acceptance; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; and BioCryst’s ability to realize the contemplated benefits of its new R&D strategy and model and successfully.

鉴于这些不确定性，您不应过度依赖这些前瞻性陈述。可能影响本文所载前瞻性陈述的因素包括：BioCryst 成功推进其管线开发计划的能力；科学顾问委员会提供的指导和建议可能无法改善 BioCryst 对潜在项目的评估或推进，也可能无法产生预期的效益；BioCryst 未来罕见病疗法的商业可行性；在研产品的持续及未来开发可能耗时超出预期，且可能无法取得积极成果；在研产品即使获得批准，也可能无法获得市场认可；BioCryst 与第三方合作的结果可能无法满足其当前预期；以及 BioCryst 实现其新研发战略和模式所预期的效益并取得成功的能力。

Contact:

联系方式：

Investors:

投资者：

investorrelations@biocryst.com

investorrelations@biocryst.com

Media:

媒体：

media@biocryst.com

media@biocryst.com